Using blood tests to improve treatment strategies for rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study measures circulating tumor DNA (ctDNA) levels in patients with stage II-III rectal cancer before, during, and after treatment. The goal is to determine if ctDNA presence or absence can indicate how well different treatments are working. Participants will provide blood samples at various intervals, and their medical records will be reviewed to assess treatment outcomes. The study aims to correlate ctDNA levels with clinical responses and survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must provide written informed consent before any study-specific procedures or interventions are performed
* Participants aged \>= 18 years
* Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum:

  * T3N0M0 - T4bN2M0

Exclusion Criteria:

* Has radiologic evidence of distant metastases at the time of screening/enrollment
* Has received prior treatment for their rectal adenocarcinoma
* Requires or has received blood transfusion within 1 month of study enrollment

Where it's running

• OHSU Knight Cancer Institute
  Portland, Oregon, United States Recruiting
• Fred Hutch
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Adel Kardosh, M.D.,Ph.D. — OHSU Knight Cancer Institute

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short course radiation therapy combined with chemotherapy for stage II-III rectal cancer

  This study is testing a new treatment plan that combines short radiation therapy with chemotherapy to see if it helps people with stage II-III rectal cancer feel better and have fewer problems after treatment.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT04703101

• Monitoring and chemotherapy before surgery for stage II-III rectal cancer

  This study tests if monitoring and chemotherapy before surgery can help people with stage II-III rectal cancer keep their organs and improve their treatment choices.

  Recruiting Early Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03594630

• Evaluating quality of life after surgery for rectal cancer

  This study looks at how surgery for rectal cancer affects the quality of life for patients over time, comparing those who received radiation therapy to those who didn’t.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT02107105

• Neoadjuvant Botensilimab and Balstilimab for Advanced Resectable Colorectal Cancer

  This phase 2 trial tests whether giving botensilimab and balstilimab before surgery can help patients with advanced, resectable colorectal cancer see better outcomes.

  Recruiting at 11 sites Phase 2 City of Hope Medical Center · Goodyear, Arizona and 10 other locations · NCT07595874

• Family genetics: who shares test results with relatives

  This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.

  Recruiting at 362 sites Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 364 other locations · NCT07143487

• Neoadjuvant FOLFOX with botensilimab and balstilimab for localized rectal cancer

  This test tries whether giving FOLFOX chemotherapy together with the immune drugs botensilimab and balstilimab before surgery helps people with localized rectal cancer achieve a complete clinical response.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06780787

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.